230 results about "K pneumoniae" patented technology

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention discloses a preparation method of Au (at) Au (at) Ag / Pt / M NPs and application of the Au (at) Au (at) Ag / Pt / M NPs in klebsiella pneumoniae detection, and belongs to the technical field of analysis and detection. The invention particularly relates to development of a signal probe and combination and assembly of the signal probe and lateral flow immunochromatography (LFIA) for klebsiella pneumoniae detection. Au (at) Au (at) Ag / Pt / MNPs is a multi-element noble metal nanoparticle with plasma resonance property, peroxidase-like activity and light stability, shows strong detection potential in three modes of colorimetric (CM), catalytic colorimetric (CL) and surface enhanced Raman scattering (SERS), and is loaded into LFIA to construct a multi-mode LFIA (CM / CL / SERS-LFIA). The kit is expected to be used for direct multimode detection of klebsiella pneumoniae in clinical sputum samples, and a new early detection strategy is provided for respiratory tract infection diseases such as klebsiella pneumoniae.

The invention discloses a bacillus strain H7 and an application thereof. The invention provides bacillus velezensis H7 or a progeny of the bacillus velezensis H7, and the preservation number of the bacillus velezensis H7 in the China Center for Type Culture Collection (CCTCC) is CCTCC NO: M 2025630. The bacillus velezensis H7 disclosed by the invention has a very good antibacterial effect on various common clinical pathogenic bacteria (including klebsiella pneumoniae, escherichia coli, candida albicans, enterobacter cloacae complex, acinetobacter baumannii and the like), and particularly shows a very high inhibition rate on some drug-resistant clinical pathogenic bacteria; therefore, the compound has important application value in development of drug and non-drug antibacterial products (such as medical antibacterial materials and the like), a new choice can be provided for drug and non-drug prevention and control of clinical pathogenic bacterium infection, and particularly, the compound has a supplementary effect in the aspects of reducing drug-resistant bacterium propagation risk and reducing drug dependence.

The invention discloses a high-temperature-resistant klebsiella pneumoniae phage, a composition of the high-temperature-resistant klebsiella pneumoniae phage and a kit, the high-temperature-resistant klebsiella pneumoniae phage is klebsiella pneumoniae phage P6AKPJS20, the preservation number of the high-temperature-resistant klebsiella pneumoniae phage is CCTCC (China Center For Type Culture Collection) NO: M20242965, and the high-temperature-resistant klebsiella pneumoniae phage has a nucleotide sequence as shown in SEQ ID No.1-6. The bacteriophage has broad-spectrum bactericidal ability, wide acid-base tolerance range and certain tolerance to chloroform and diethyl ether, and can still maintain high activity while splitting target bacteria; meanwhile, the bacteriophage has good tolerance to high temperature and can adapt to various application conditions in production.

The invention discloses a microbial marker related to refractory diarrhea, a product and application of the microbial marker, and relates to the technical field of biomedicine. According to the present invention, the microbial marker comprises any one or more of Ruminococcus sp, Bifidobacterium longum, Lachnospiraceae bacterium, Klebsiella pneumoniae, Rosa mucilaginosa, and Coprococcus catenus, and the microbial marker comprises any one or more of the following components: the Ruminococcus sp, the Bifidobacterium longum, the Lachnospiraceae bacterium, the Klebsiella pneumoniae, the Rosa mucilaginosa, and the Coprococcus catenus. The microbial marker can serve as a detection marker to be applied to diagnosis of refractory diarrhea patients, and when the refractory diarrhea patients are diagnosed, the microbial marker is completely noninvasive and high in accuracy.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 and application thereof, and relates to the technical field of biology. The klebsiella pneumoniae bacteriophage vBKpnPGZMUVR2301 is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, the preservation address is the 5th floor of the building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, and the preservation number is GDMCC No: 65268-B1. The bacteriophage keeps stable titer in a wide pH range (4-10) and a temperature interval (4-50 DEG C), and the highest titer can reach more than 109 pfu / mL. The bacteriophage can efficiently split klebsiella pneumoniae. The invention provides powerful technical support for developing novel antibacterial drugs and treatment schemes for klebsiella pneumoniae, and shows wide application prospect and potential clinical value.

The invention discloses an application of NSC348884 in preparation of an antibacterial drug, the bacteria of the NSC348884 are gram-negative bacteria or drug-resistant gram-negative bacteria, and the gram-negative bacteria are acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa or klebsiella pneumoniae; based on an antibacterial drug high-throughput screening technology, it is found from 1280 small molecule compounds that the benzimidazole compound NSC348884 has direct bacteriostasis and sterilization effects on gram-negative bacteria and drug-resistant gram-negative bacteria, and no drug resistance is generated after the benzimidazole compound NSC348884 is continuously applied for 14 days. Further research shows that NSC348884 can interfere with lipid synthesis of gram-negative bacterium cell membranes, inhibit formation of biological membranes and induce lipid metabolism disorder, so that bacteriostatic and bactericidal effects are achieved. In addition, the NSC348884 can also enhance the sensitivity of the drug-resistant bacteria to the imipenem and the polymyxin B.

The invention relates to the technical field of molecular biology and pathogenic microorganism detection, and discloses a Klebsiella pneumoniae and Escherichia coli synchronous detection method based on RPA-CRISPR / Cas12a and application, and the method comprises the following steps: extracting DNA from a sample, carrying out isothermal amplification by adopting an RPA primer designed aiming at a Klebsiella pneumoniae rcsA gene and an Escherichia coli uriA gene, and carrying out amplification by adopting an RPA primer designed aiming at a Klebsiella pneumoniae RcsA gene and an Escherichia coli uriA gene; a detection system containing Cas12a enzyme, crRNA and a fluorescence report substrate is constructed, and a result is interpreted through a fluorescence or lateral flow chromatography test strip. Detection can be completed within 70 minutes at the constant temperature of 37 DEG C, the sensitivity reaches 5 * 10 copies / mu L, the specificity is high, no cross reaction exists, the kit is suitable for clinical early screening, hospital infection monitoring and on-site POCT application, and an efficient and reliable new tool is provided for pathogen diagnosis.

The antibody disclosed by the invention can specifically target high-virulence klebsiella pneumoniae of different serotypes, and specifically targets klebsiella pneumoniae of K1 and K2 serotypes. The antibody disclosed by the invention can be combined with high-toxicity klebsiella pneumoniae extracellular capsular polysaccharide with high affinity, has very strong neutralizing activity on klebsiella pneumoniae, and can mediate complement and mature neutrophil to neutralize and kill bacteria in an in-vitro killing experiment, so that the bacterial density is reduced, and the killing effect is improved. The traditional Chinese medicine composition can effectively prevent and treat high-toxicity klebsiella pneumoniae clinical infection and effectively improve pulmonary infection, provides a way for solving the problems of klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance in preventing, diagnosing and treating klebsiella pneumoniae infection, and has important value in development of a new generation of klebsiella pneumoniae medicine.

The invention belongs to the technical field of biology, and particularly relates to a primer probe composition and a kit for detecting lower respiratory tract infection pathogens. The primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae, and the primer probe composition is used for detecting mycobacterium tuberculosis, mycobacterium avium, mycobacterium abscessus, mycobacterium kansasii, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and haemophilus influenzae. The composition is one or more of a composition for detecting staphylococcus aureus, a composition for detecting streptococcus pneumoniae, a composition for detecting escherichia coli, a composition for detecting moraxella catarrhalis, a composition for detecting serratia marcescens, a composition for detecting mycoplasma pneumoniae, a composition for detecting candida albicans or a composition for detecting adenovirus; the RAA-RDB technology has the core advantages of rapidness, high sensitivity, low cost and easy operation, and is especially suitable for multiple pathogen screening and basic medical application.

The invention discloses a construction and evaluation method of a PM2.5 induced chronic obstructive pulmonary disease acute exacerbation mouse model, and relates to the technical field of disease animal models. The invention aims to evaluate whether PM2.5 can induce acute exacerbation of COPD through a mouse model, a COPD model is established by adopting combined treatment of smoking and lipopolysaccharide (LPS), and an infectious AECOPD model is established by using common klebsiella pneumoniae (KP) nasal drop on the basis. Meanwhile, PM2.5 processing is added on the basis of the COPD model, and the effect of PM2.5 on acute exacerbation of COPD is evaluated. Through comparison with a classical model (an infectious AECOPD model), the potential effect of PM2.5 in induction of acute exacerbation of COPD is evaluated, and an important reference is provided for future research on an AECOPD animal model induced by air pollution.

The present invention relates to the pharmaceutical field, and provides a boric acid β-lactamase inhibitor or a use thereof. The boric acid β-lactamase inhibitor is a compound shown in formula (I), or an optical isomer or a pharmaceutically acceptable salt thereof: formula (I). The ultra-broad-spectrum boric acid β-lactamase inhibitor of the present invention has an inhibition effect on A, B, C, and D enzymes, and carbapenem drug-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii, and Pseudomonas aeruginosa.

The invention belongs to the technical field of biological medicine, and particularly discloses application of tea polyphenol combined with meropenem to preparation of a medicine for resisting carbapenem drug-resistant bacteria, and the carbapenem drug-resistant bacteria are animal source blaNDM-5 positive escherichia coli and / or klebsiella pneumoniae. A trace bouillon chessboard method, a cefoxitin hydrolysis test, a time-sterilization curve, a greater wax moth infection model and the like prove that the tea polyphenol and carbapenem antibiotic meropenem generate a good synergistic antibacterial effect, and the tea polyphenol can also inhibit the activity of NDM-5 enzyme; meanwhile, the treatment and protection effects of meropenem on a greater wax moth infection model are improved. It is found for the first time that tea polyphenol can reverse the drug resistance of carbapenem drug-resistant bacteria to meropenem and enhance the antibacterial activity of meropenem to carbapenem drug-resistant bacteria, the synergistic effect is remarkable, use is easy, popularization is easy, and good application value is achieved.

The present invention provides a fusion protein KP-Ag1 used as a Klebsiella pneumoniae vaccine antigen, which is composed of KP6 protein, KP21 protein and KP24 protein connected by a flexible amino acid Linker; wherein, the amino acid sequence of the KP6 is SEQ ID NO:4, the amino acid sequence of the KP21 is SEQ ID NO:5, and the amino acid sequence of the KP24 is SEQ ID NO:6. The present invention also provides its expression vector and recombinant engineering diagram, as well as its application as a Klebsiella pneumoniae antigen. The antigen protein prepared by the method described in the present invention can effectively stimulate the body to produce a higher humoral immune response, and can provide obvious protection against lethal-dose Klebsiella pneumoniae infection, and can be used as a candidate antigen for Klebsiella pneumoniae vaccine.

This invention discloses nucleic acid aptamers that specifically bind to the OmpK36 protein and their applications. Through analysis and screening, aptamers APT-1 and APT-2 that specifically bind to the OmpK36 protein were obtained. Nucleic acid aptamer APT-1 can specifically bind to outer membrane polypeptides, while nucleic acid aptamer APT-2 can specifically bind to polypeptides specific to Klebsiella pneumoniae. Both can bind to the OmpK36 protein to form a complex structure, which can be used for the specific detection of Klebsiella pneumoniae, providing convenience for clinical detection, diagnosis and treatment, and exclusion detection of specific pathogens in SPF animals.

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.

The present invention relates to novel oligosaccharide-carrier protein conjugates of formula (I) and their use as pharmaceuticals, particularly as vaccines. The present invention also relates to related aspects, including oligosaccharide intermediates of formulas (II) and (III) and methods for preparing such conjugates. Furthermore, the present invention relates to pharmaceutical compositions comprising the oligosaccharide-carrier protein conjugates and to the use of oligosaccharide-carrier protein conjugates of formula (IV) in biological assays. [Formula 1] JPEG2025536393000131.jpg85168

The application discloses application of T1FR protein in inhibition of Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae, and relates to the field of biotechnology. T1fr The biological factor T1FR protein encoded by the gene can inhibit Klebsiella pneumoniae and Salmonella enteritidis type I fimbriae adhesion factors, and can effectively reduce the use of antibiotics and relieve the drug resistance of Klebsiella pneumoniae and Salmonella by inhibiting pathogenic bacteria adsorption and colonization in human and animal tissues, thereby providing a theoretical basis and an important reference scheme for controlling bacterial infection and biofilm formation.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

The invention provides a broad-spectrum bacteriophage capable of efficiently splitting carbapenem-resistant klebsiella pneumoniae and application of the broad-spectrum bacteriophage, and belongs to the technical field of biological medicines. The bacteriophage is named as P146043, the host spectrum of the bacteriophage is wide, the bacteriophage can be used for CRKP strains of four ST genotypes and eight KL capsule types, and the antibacterial effect is good; meanwhile, good acid and alkali resistance and temperature stability are achieved; and the bacteriophage has a synergistic antibacterial effect with other bacteriophages, so that the antibacterial time can be prolonged. The P146043 provides an effective method and a new prevention and treatment thought for prevention and treatment of CRKP infectious disease infection, and has a good application prospect.

The present invention provides a Klebsiella pneumonia KPC-Pal recombinant protein, which is composed of a KPC peptide segment extracted from the Klebsiella pneumonia KPC-2 protein and a Pal peptide segment extracted from the Klebsiella pneumonia Pal protein connected by a polypeptide linker, wherein the amino acid sequence of the Klebsiella pneumonia KPC-2 protein is SEQ ID NO: 3, and the amino acid sequence of the Klebsiella pneumonia Pal protein is SEQ ID NO: 4. The present invention also provides its expression vector and recombinant engineered bacteria, as well as its application in the preparation of a preparation for diagnosing, preventing or treating Klebsiella pneumonia infection. The Klebsiella pneumonia KPC-Pal recombinant protein provided by the present invention can effectively stimulate the body to cause a protective immune response, thereby resisting the lethal infection of Klebsiella pneumonia.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The invention discloses a primer group, a kit and a detection method for high-risk clone typing detection of klebsiella pneumoniae ST11, the primer group comprises one or more amplification primer pairs and probes for detecting high-risk clone marker genes (including bmr3, sdaC, pyrB, mltC and ppsC) of klebsiella pneumoniae and ST11, and the high-risk clone typing detection of klebsiella pneumoniae and ST11 is realized by using a method of asymmetric fluorescent PCR amplification and melting curve. According to the present invention, the mutation type sample and the wild type sample are subjected to the differentiated detection so as to form the stable PCR reaction kit system, such that the clinical klebsiella pneumoniae pathogen can be efficiently and accurately detected, and the ST11 typing detection can be performed on the ST11 high-risk cloning marker gene. A complete system formed by the primer group, the kit and the detection method has high specificity and accuracy, klebsiella pneumoniae pathogens and ST11 high-risk clone typing can be effectively detected, rapid, efficient and low-cost detection can be realized, the detection time is greatly shortened, and large-scale application is facilitated.

The application belongs to the technical field of medicine and pharmacy, and particularly relates to application of vanillin in preparation of a Klebsiella pneumoniae capsule inhibitor. The application relates to application of vanillin in preparation of an inhibitor for inhibiting formation, adhesion or function of a Klebsiella pneumoniae capsule, and related antibacterial or anti-infection products, wherein the vanillin reduces pathogenicity of Klebsiella pneumoniae by inhibiting capsule synthesis. It is disclosed that the vanillin can effectively inhibit formation of a Klebsiella pneumoniae capsule and reduce viscosity of bacteria, and can effectively treat mice infected with Klebsiella pneumoniae.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae, escherichia coli and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which are characterized in that a phoE target gene is selected for primer and probe design to ensure that cross amplification of related bacteria is not caused, so that the detection specificity requirement of actual klebsiella pneumoniae is met; the Klebsiella pneumoniae and the escherichia coli can be identified at the same time, the source of the drug-resistant gene KPC can be judged, and the method is very important for clinical precise diagnosis and treatment.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

The present invention discloses a Klebsiella phage and its application, belonging to the field of life science and technology. The Klebsiella phage is deposited in the General Microbiology Center of the China Committee for Culture Collection of Microorganisms, with the deposit number CGMCC No. 46000, the deposit date being July 22, 2024, and the taxonomic name being Klebsiella phage, named FK9. The phage provided by the present invention is a biological means capable of efficiently killing Klebsiella pneumoniae, featuring high efficiency and specificity and small side effects. It can prevent and treat pneumonia caused by Klebsiella pneumoniae without disrupting the balance of the body's flora, which is incomparable to antibiotics and other antibacterial drugs. At the same time, it contributes to the sustainable development of the healthy medical system.

The invention belongs to the technical field of microbiological detection, and particularly relates to a Klebsiella pneumoniae MLST typing primer group and method based on a hospital localized microbiological mNGS platform. The primer group comprises primer pairs for amplifying an rpoB gene, an infB gene, a pgi gene, a phoE gene, a gapA gene, an mdh gene and a tonB gene, and corresponding nucleotide sequences are as shown in SEQ ID NO: 1-14. According to the technical characteristics of short sequencing read length (50 bp) and single-ended sequencing of a next-generation sequencing platform in a hospital, the primer group for Klebsiella pneumoniae MLST housekeeping gene amplification is redesigned, and amplicons are adaptive to the sequencing working principle of the existing next-generation sequencing platform in the hospital by optimizing the length and position of the amplicons. By utilizing the primer group, the kit or the method, the genetic relationship between hospital infection pathogenic bacteria can be quickly and accurately judged (within 24 hours), the timeliness and scientificity of infection prevention and control are remarkably improved, and the primer group, the kit or the method have a wide clinical application prospect.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

The invention discloses an application of combination of lefamulin and polymyxin B in preparation of a bactericide. According to the invention, lefamorin and polymyxin B are used for synergistically killing bacteria, so that the antibacterial activity of polymyxin B on gram-negative bacteria which are drug-resistant and sensitive to polymyxin B, such as escherichia coli, klebsiella pneumoniae and the like, can be effectively recovered in vitro and in vivo; in addition, lefamoline has no cytotoxicity to mammalian cells, and the application of lefamoline effectively reduces the therapeutic dose of polymyxin B and reduces the side effect risk of polymyxin B to mammals.